



# STEP THERAPY CRITERIA

Last Updated: 03/01/2023

This document contains clinical criteria for coverage of certain drugs that may be covered under your pharmacy benefit. This document is accurate as of the last update date and is subject to change.

Please note that additional restrictions and exclusions to drug coverage may apply. You can search for your drugs on the "Drug Search" online tool for your formulary found at:

<https://www.providencehealthplan.com/members/pharmacy-resources>

This is not a guarantee of coverage or benefits. Please check your member handbook to verify coverage or call Providence Health Plan Customer Service at 503-574-7500 or 1-800-878-4445 (TTY: 711). Service is available five days a week, Monday through Friday, between 8 a.m. and 6 p.m.

## ANTI-GLAUCOMA AGENTS

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

BIMATOPROST 0.03% EYE DROPS, LUMIGAN, RHOPRESSA, TAFLUPROST, VYZULTA, ZIOPTAN

### **CRITERIA**

#### **REQUIRED MEDICAL INFORMATION:**

An adequate trial, contraindication, or intolerance to the use of formulary generic latanoprost 0.005% eye drops.

#### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes

## ANTIDEPRESSANTS

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

FETZIMA, TRINTELLIX, VIIBRYD, VILAZODONE HCL

### **CRITERIA**

#### REQUIRED MEDICAL INFORMATION:

1. The patient is currently established on therapy with the requested medication (Note: Medications obtained as samples, coupons, or any other method of obtaining medications outside of an established health plan benefit are NOT considered established on therapy) OR
2. Documented trial, intolerance, or contraindication to one formulary generic antidepressant, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), bupropion, or mirtazapine. Examples of formulary SSRI or SNRI's include but are not limited to the following: citalopram, sertraline, paroxetine, venlafaxine, duloxetine, escitalopram, and fluoxetine.

#### COVERAGE DURATION:

Authorization will be approved until no longer eligible with the plan, subject to formulary and/or benefit changes.

# ANTIEPILEPTIC MEDICATIONS

---

## **MEDICATION(S) SUBJECT TO STEP THERAPY**

APTIOM, BANZEL, BRIVIACT 10 MG TABLET, BRIVIACT 10 MG/ML ORAL SOLN, BRIVIACT 100 MG TABLET, BRIVIACT 25 MG TABLET, BRIVIACT 50 MG TABLET, BRIVIACT 75 MG TABLET, FYCOMPA, RUFINAMIDE, XCOPRI

## **CRITERIA**

### **COVERED USES:**

Seizure Disorder

### **REQUIRED MEDICAL INFORMATION:**

1. The patient is currently established on therapy with the requested medication (Note: starting on samples will not be considered established on therapy)

OR

2. Documentation of trial and failure of at least one formulary preferred generic antiepileptic medication (divalproex sodium, valproic acid, felbamate, lamotrigine, topiramate, carbamazepine, phenytoin, levetiracetam or clobazam)

### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary and/or benefit changes.

# ANTIPSYCHOTICS: MAJOR DEPRESSIVE DISORDER

---

## MEDICATION(S) SUBJECT TO STEP THERAPY

REXULTI

### CRITERIA

#### REQUIRED MEDICAL INFORMATION:

1. For all requests, the patient must have a Food and Drug Administration (FDA) labeled indication for the requested agent or use to treat the indication is supported in drug compendia (such as the American Hospital Formulary Service-Drug Information (AHFS-DI) or Truven Health Analytics' DRUGDEX® System.)
2. One of the following criteria must be met:
  - a. The patient is currently established on therapy with the requested medication (Note: Medications obtained as samples, coupons, or any other method of obtaining medications outside of an established health plan benefit are NOT considered established on therapy) OR
  - b. All the following indication-specific criteria must be met:
    - i. For adjunctive treatment of major depressive disorder (Rexulti®):
      1. Documentation of current use of an antidepressant (for example: citalopram, sertraline, paroxetine, duloxetine, mirtazapine, venlafaxine) AND
      2. Documented trial, failure, intolerance, or contraindication to quetiapine and aripiprazole
    - ii. For schizophrenia: Documented trial, failure, intolerance, or contraindication to two formulary, generic, atypical antipsychotics (for example: quetiapine, olanzapine, ziprasidone, risperidone, aripiprazole)
    - iii. For bipolar disorder: Documented trial, failure, intolerance, or contraindication to two formulary, generic medications for bipolar disorder (for example: lithium, quetiapine, lamotrigine, divalproex, aripiprazole, risperidone, olanzapine, ziprasidone), one of which must be a formulary, generic atypical antipsychotic

#### COVERAGE DURATION:

Authorization will be approved until no longer eligible with the plan, subject to formulary and/or benefit changes.

## ANTIPSYCHOTICS: SCHIZOPHRENIA / BIPOLAR DISORDER

---

### MEDICATION(S) SUBJECT TO STEP THERAPY

ASENAPINE MALEATE, CAPLYTA, FANAPT, LATUDA, LURASIDONE HCL, LYBALVI, REXULTI, SAPHRIS, SECUADO, VRAYLAR

### CRITERIA

#### REQUIRED MEDICAL INFORMATION:

1. For all requests, the patient must have a Food and Drug Administration (FDA) labeled indication for the requested agent or use to treat the indication is supported in drug compendia (such as the American Hospital Formulary Service-Drug Information (AHFS-DI) or Truven Health Analytics' DRUGDEX® System.)
2. One of the following criteria must be met:
  - a. The patient is currently established on therapy with the requested medication (Note: Medications obtained as samples, coupons, or any other method of obtaining medications outside of an established health plan benefit are NOT considered established on therapy) OR
  - b. All the following indication-specific criteria must be met:
    - i. For adjunctive treatment of major depressive disorder (Rexulti®):
      1. Documentation of current use of an antidepressant (for example: citalopram, sertraline, paroxetine, duloxetine, mirtazapine, venlafaxine) AND
      2. Documented trial, failure, intolerance, or contraindication to quetiapine and aripiprazole
    - ii. For schizophrenia: Documented trial, failure, intolerance, or contraindication to two formulary, generic, atypical antipsychotics (for example: quetiapine, olanzapine, ziprasidone, risperidone, aripiprazole)
    - iii. For bipolar disorder: Documented trial, failure, intolerance, or contraindication to two formulary, generic medications for bipolar disorder (for example: lithium, quetiapine, lamotrigine, divalproex, aripiprazole, risperidone, olanzapine, ziprasidone), one of which must be a formulary, generic atypical antipsychotic

#### COVERAGE DURATION:

Authorization will be approved until no longer eligible with the plan, subject to formulary and/or benefit changes.

# ELIDEL

---

## **MEDICATION(S) SUBJECT TO STEP THERAPY**

ELIDEL, PIMECROLIMUS

## **CRITERIA**

### **COVERED USES:**

All medically accepted indications not otherwise excluded from the benefit.

### **REQUIRED MEDICAL INFORMATION:**

Documented trial or contraindication to tacrolimus 0.1% ointment or tacrolimus 0.03% ointment

### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes

## **GIP/GLP-1 RECEPTOR AGONISTS:PREFERRED**

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

OZEMPIC, RYBELSUS, TRULICITY, VICTOZA 2-PAK, VICTOZA 3-PAK

### **CRITERIA**

#### **COVERED USES:**

All Food and Drug Administration (FDA) approved indications not otherwise excluded from the benefit.

#### **REQUIRED MEDICAL INFORMATION:**

1. One (1) of the following:

a. History of use of a medication containing metformin within the previous 180 days (verified by pharmacy claims), or

b. Documentation of trial, intolerance, or contraindication to metformin

AND

2. For exenatide (Byetta®), exenatide ER (Bydureon®), and lixisenatide (Adlyxin®): Documentation of trial, contraindication or intolerance to at least TWO (2) of the preferred glucagon-like peptide-1 (GLP-1) receptor agonists: liraglutide (Victoza®), semaglutide (Ozempic®/Rybelsus®), or dulaglutide (Trulicity®)

#### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes.



## HECTOROL/ZEMPLAR

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

DOXERCALCIFEROL 0.5 MCG CAP, DOXERCALCIFEROL 1 MCG CAPSULE,  
DOXERCALCIFEROL 2.5 MCG CAP, PARICALCITOL 1 MCG CAPSULE, PARICALCITOL 2 MCG  
CAPSULE, PARICALCITOL 4 MCG CAPSULE, ZEMPLAR 1 MCG CAPSULE, ZEMPLAR 2 MCG  
CAPSULE

### **CRITERIA**

#### **COVERED USES:**

All medically accepted uses not otherwise excluded from the benefit.

#### **REQUIRED MEDICAL INFORMATION:**

Documentation of trial, intolerance, or contraindication to calcitriol

#### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes.

# LUCEMYRA

---

## **MEDICATION(S) SUBJECT TO STEP THERAPY**

LUCEMYRA

## **CRITERIA**

All Food and Drug Administration (FDA) approved indications not otherwise excluded from the benefit.

## **REQUIRED MEDICAL INFORMATION:**

Patient must have tried clonidine

## **COVERAGE DURATION:**

Authorization may be reviewed annually to assess continued medical necessity and effectiveness of medication

# NEUPRO

---

## **MEDICATION(S) SUBJECT TO STEP THERAPY**

NEUPRO

## **CRITERIA**

### **COVERED USES:**

All Food and Drug Administration (FDA) approved indications not otherwise excluded from the benefit.

### **REQUIRED MEDICAL INFORMATION:**

Documented trial or contraindication to ropinirole (Requip®) AND pramipexole (Mirapex®)

### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes.

# ONGENTYS

---

## **MEDICATION(S) SUBJECT TO STEP THERAPY**

ONGENTYS

## **CRITERIA**

### **COVERED USES:**

All medically accepted indications.

### **REQUIRED MEDICAL INFORMATION:**

Documented trial, intolerance, or contraindication to generic entacapone

### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes

# OVERACTIVE BLADDER MEDICATIONS

---

## MEDICATION(S) SUBJECT TO STEP THERAPY

MYRBETRIQ

## CRITERIA

### COVERED USES:

All medically accepted indications not otherwise excluded from the benefit

### REQUIRED MEDICAL INFORMATION:

One of the following must be met:

1. Trial, intolerance, or contraindication to one of the following:
  - a. oxybutynin
  - b. tolterodine
  - c. solifenacin
  - d. darifenacin
  - e. trospium
2. Use is for treatment of neurogenic detrusor overactivity (NDO) in pediatric patients three years and older and weighing 35 kilograms or more

Note: Contraindications to anticholinergic agents include delirium, dementia/cognitive impairment, preexisting issue with chronic constipation, urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma.

### COVERAGE DURATION:

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes

## PHOSPHATE BINDERS

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

AURYXIA, FOSRENOL, LANTHANUM CARBONATE, PHOSLYRA, RENAGEL, RENVELA 0.8 GM POWDER PACKET, RENVELA 2.4 GM POWDER PACKET, SEVELAMER 0.8 GM POWDER PACKET, SEVELAMER 2.4 GM POWDER PACKET, SEVELAMER HCL, VELPHORO

### **CRITERIA**

#### **COVERED USES:**

All medically accepted indications not otherwise excluded from the benefit.

#### **REQUIRED MEDICAL INFORMATION:**

Documentation of trial, contraindication, or intolerance to calcium acetate tablets/capsules (Phos-Lo®) AND sevelamer carbonate tablets (Renvela®)

For Auryxia® to control iron deficiency anemia:

Documentation of trial and failure, contraindication, or intolerance to iron supplementation. Failure is defined as failure of hemoglobin to return to normal by eight weeks of iron supplementation.

Intolerance will include constipation that is not controlled by increasing fiber in diet, docusate, bulk forming laxatives (Metamucil®, Citrucel®, Benefiber®), or polyethylene glycol (Miralax®).

#### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes

## SEROTONIN ANTAGONISTS

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

SANCUSO

### **CRITERIA**

#### **COVERED USES:**

All Food and Drug Administration (FDA) approved indications not otherwise excluded from the benefit.

#### **REQUIRED MEDICAL INFORMATION:**

Documented trial, failure, intolerance or contraindication to ondansetron AND granisetron tablets.

#### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes.

# SOOLANTRA

---

## **MEDICATION(S) SUBJECT TO STEP THERAPY**

IVERMECTIN 1% CREAM, SOOLANTRA

## **CRITERIA**

### **COVERED USES:**

All Food and Drug Administration (FDA) approved indications not otherwise excluded from the benefit.

### **REQUIRED MEDICAL INFORMATION:**

Documented trial, failure, intolerance or contraindication to metronidazole topical gel, cream, or lotion

### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary or benefit changes

### **QUANTITY LIMIT:**

45 grams per 30 days



## TOPICAL ANTIBIOTICS

---

### **MEDICATION(S) SUBJECT TO STEP THERAPY**

ALTABAX, XEPI

### **CRITERIA**

#### **COVERED USES:**

All medically accepted indications not otherwise excluded from the benefit.

#### **REQUIRED MEDICAL INFORMATION:**

Documented trial and failure, intolerance or contraindication to mupirocin 2% ointment

#### **COVERAGE DURATION:**

Authorization will be approved until no longer eligible with the plan, subject to formulary and/or benefit changes